Is Ocugen About to Beat Moderna in This One Market?

Is Ocugen About to Beat Moderna in This One Market?

Source: 
Motley Fool
snippet: 
  • Ocugen is taking longer than expected to bring its vaccine candidate Covaxin to the U.S. adult market.
  • The company will apply for approval instead of emergency authorization.
  • Ocugen surprised investors recently when it applied for authorization in a specific population.